How to Measure the Benefit of Chemotherapy-Free Interval in a Trial with Maintenance Targeted Therapy? The Importance Combined Endpoints

ESGO eAcademy, Bradley Monk, 116819

How to Define Platinum-Resistance or Sensitivity after Several Lines of Treatment?

ESGO eAcademy, Jonathan Ledermann, 116818

Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - CON

ESGO eAcademy, Sandro Pignata, 116817

Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - PRO

ESGO eAcademy, Mansoor Raza Mirza, 116816

Welcome and Introduction: The Changing Landscape of Clinical Trials in the Era of Targeted and Immunologic Therapies: Different Patient Selection, New Endpoints, New Responsible Criteria

ESGO eAcademy, Nicoletta Colombo, 116815

Possible role of robotics in ERAS

ESGO eAcademy, Eric Lambaudie, 105096

What is the place of sentinel procedures in gynecologic Oncology?

ESGO eAcademy, Rene H.M. Verheijen, 105095

Robotic single-site pelvic lymphadenectomy

ESGO eAcademy, Liliana Mereu, 106938

Endoscopic staging in early stage ovarian cancer

ESGO eAcademy, Eric Lambaudie, 106937

Key Lecture: Critical considerations on Robotic Surgery for the treatment of Endometrial Cancer

ESGO eAcademy, Angelo Maggioni, 105137

What progress is made and expected the coming decade in endoscopic (non-robotic) gynaecological surgery ?

ESGO eAcademy, Farr Nezhat, 105090

Single site robotic hysterectomy

ESGO eAcademy, Fatih Sendag, 105088

Compartment imaging with fluorescence

ESGO eAcademy, Rainer Kimmig, 105087

New robots and implementation

ESGO eAcademy, Rene H.M. Verheijen, 105086

Paraaortic lymphadenectomy and surgical approach

ESGO eAcademy, Fabrice Narducci, 105085

Robotic radical trachelectomy

ESGO eAcademy, M. Faruk Kose, 105084

Robotic-assisted radical hysterectomy: oncology outcomes

ESGO eAcademy, Vanna Zanagnolo, 105083

Key lecture: Radical hysterectomy: Overview of the different techniques of parametrial dissection

ESGO eAcademy, Rainer Kimmig, 105082

Abstracts for Meetings

ESGO eAcademy, Sean Kehoe, 108687

Clinical Trials

ESGO eAcademy, Sean Kehoe, 108688

Journals for Gynaecological Oncology

ESGO eAcademy, Sean Kehoe, 108689

Other Publications

ESGO eAcademy, Sean Kehoe, 108690

The Oral Presentation

ESGO eAcademy, Sean Kehoe, 108691

Constructing a Paper

ESGO eAcademy, Christina Fotopoulou, 108692

The Poster Presentation

ESGO eAcademy, Christina Fotopoulou, 108693

Why Are Papers Rejected?

ESGO eAcademy, Christina Fotopoulou, 108694

Statistical Basic Facts

ESGO eAcademy, Mariana Díaz Almirón, 108695

European Reference Network

ESGO eAcademy, Francois Golfier, 99309

Future Perspectives in Gestational Trophoblastic Disease

ESGO eAcademy, Leon Massuger, 99308

PSTT/ETT

ESGO eAcademy, Barry Hancock, 99307

When EMACO Does Not Cure

ESGO eAcademy, Michael Seckl, 99305

Case Report Hi Dose

ESGO eAcademy, Kirsty Balachandran, 99304

Treatment of High Risk Gestational Trophoblastic Disease

ESGO eAcademy, John Tidy, 99303

Case: High Risk Gestational Trophoblastic Disease

ESGO eAcademy, Mireille Vree, 99302

Treatment of Low Risk Gestational Trophoblastic Disease

ESGO eAcademy, John Coulter, 99301

Case: MTX Resistance

ESGO eAcademy, Sam Schoenmakers, 99300

Histologic and Immunohistochemic Features of Trophoblastic Disease

ESGO eAcademy, Sophie Patrier, 99299

Case Report Pathology

ESGO eAcademy, Gwendoline Side-Pfennig, 99298

HCG in Gestational Trophoblastic Disease

ESGO eAcademy, Teun van Herwaarden, 99295

Case: Clinical Consequences of Different hCG Assays

ESGO eAcademy, Yalck Eysbouts, 99294

History of Gestational Trophoblastic Disease

ESGO eAcademy, Rene H.M. Verheijen, 99293

Immunotherapy Represents the Future for Ovarian Cancer

ESGO eAcademy, Bradley Monk, 96876

Immunotherapy Has Never Worked and Will Never Work in Ovarian Cancer

ESGO eAcademy, Eric Pujade-Lauraine, 96875

How To Negotiate Support with Pharma Companies for Sponsored Trials

ESGO eAcademy, Andreas Du Bois, 96873

How To Write a Grant for Academic Trials (Investigator-Initiated)

ESGO eAcademy, Sandro Pignata, 96872

The Hurdles of Conducting Trials across Different Countries: Focus on EU Regulations and Differences Which May Constitute Barriers to Run an ENGOT Trial

ESGO eAcademy, Jacobus Pfisterer, 96871

The Challenge of Initiating a National Cooperative Trial Group: Tricks and Tips

ESGO eAcademy, Mansoor Raza Mirza, 96870

Outside EU Regulations: Activating a Study in Switzerland

ESGO eAcademy, Cristiana Sessa, 96983

Managing Depression in Cancer Patients

ESGO eAcademy, Madeline Li & Gary Rodin, 63587

Reversing Mutated p53 to Wild Type

ESGO eAcademy, Sevilay Altintas, 63068

Inhibiting the Gain-of-Function of Mutated p53

ESGO eAcademy, Nicole Concin, 63067

Why Signatures Miss the Goal in Ovarian Cancer

ESGO eAcademy, MICHAEL BIRRER, 63066

Why Signatures Are the Best Way to Identify Subgroups in Ovarian Cancer

ESGO eAcademy, Charlie Gourley, 63065

The Tricky Decision to Allow Cross-Over or Not in a Trial

ESGO eAcademy, Bradley J. Monk, 63064

Funding Options, Legal Aspect and Insurance Hurdles, How To Select Centers for Surgical Trials?

ESGO eAcademy, Jacobus Pfisterer, 63060

What Are the Endpoints and Do We Have the Right Questionnaires for QOL? What Are the Open Questions in Relapse Ovarian Cancer?

ESGO eAcademy, Philip Harter, 63061

Anaesthetic complications

ESGO eAcademy, Oliver Groll, 63116

Injury of the gastrointestinal tract

ESGO eAcademy, Gökhan Yagci, 63094

Robotic debulking surgery

ESGO eAcademy, Javier Magrina, 63093

EU reimbursement update and the role of medical expertise in Driving Dr.G change

ESGO eAcademy, Susanne Habetha, 63134

Chance of cost reduction and increase of efficiency in robotic surgery

ESGO eAcademy, Petur Reynisson, 63133

Cost analysis in endometrial cancer patients

ESGO eAcademy, Frederic Goffin, 63132

Cost evaluation (French analysis)

ESGO eAcademy, Eric Lambaudie, 63131

How to implement a registry?

ESGO eAcademy, Eric Lambaudie, 63092

The 'Art of Docking': Key for successful robotic surgery

ESGO eAcademy, Henrik Falconer, 63130

Robotic skills assessment: to score or not score ?

ESGO eAcademy, Henk W.R. Schreuder, 63088

Compartment visualization in embryologically defined surgery

ESGO eAcademy, Martin Heubner, 63129

Education in robotics: The U.S. experience

ESGO eAcademy, Gokhan S. Kilic, 63089

Applicability and feasibility of laparoscopic surgery of uterine cancer in patients with BMI under 30. Evaluation of a policy in favor of minimal invasive surgery in a single center

ESGO eAcademy, Denis Querleu, 63126

Perioperative morbidity and outcome analysis of robotically assisted laparoscopic radical hysterectomy

ESGO eAcademy, Fabrice Narducci, 63125

Robotic surgery and technique of radical hysterectomy in cervical and endometrial cancer

ESGO eAcademy, Angelo Maggioni, 63124

Evidence for adequate quality in radical hysterectomy by endoscopy

ESGO eAcademy, Roberto Tozzi, 63123

Robotic Surgery – less morbidity maintaining efficacy?

ESGO eAcademy, Loic Boulanger, 63143

Present and future development of robotic surgery in gynecology: Visions, expectations and demands

ESGO eAcademy, Ignace Vergote, 63083

SPECT/CT & sentinel node – an alternative to lymphadenectomy

ESGO eAcademy, Ronald P. Zweemer, 63121

Adhesion prevention in robotic myomectomy

ESGO eAcademy, Jasper Verguts, 63151

The need for guidelines and standards in robotic surgery

ESGO eAcademy, Dezita Taylor, 63157

New robotic systems

ESGO eAcademy, Rene H.M. Verheijen, 63138

Innovations of robotically assisted laparoscopy – Single port surgery

ESGO eAcademy, Fatih Sendag, 63136

RoundTable (Questions&Answers) of State of the Art Conference

ESGO eAcademy, Session Speakers, 62459

Patient´s expectations and perspectives about cancer care in ovarian cancer

ESGO eAcademy, Elena Ioana Braicu, 62458

Follow up of advanced stage invasive ovarian cancers

ESGO eAcademy, Gordon J.S. Rustin, 62457

Follow up of early stage invasive ovarian cancer, fertility sparing treatment

ESGO eAcademy, Rene H.M. Verheijen, 62456

Non epithelial ovarian tumours

ESGO eAcademy, Nicoletta Colombo, 62455

Borderline ovarian tumor follow up

ESGO eAcademy, Philippe Morice, 62454

Familial risk and its management

ESGO eAcademy, Usha Menon, 62453

Imaging strategies for follow up

ESGO eAcademy, Nandita de SOUZA, 62451

Imaging strategies for follow up

ESGO eAcademy, Manuela LUDOVISI, 62452

The Role of the Pathologist in Planning Follow up

ESGO eAcademy, Silvestro CARINELLI, 62450

The Role of Biomarkers in the Follow up in Ovarian Cancer

ESGO eAcademy, Massimo GION, 62449

Take home message of State of the Art Conference

ESGO eAcademy, Rainer Kimmig, 62446

RoundTable (Questions&Answers) of State of the Art Conference

ESGO eAcademy, Panel, 62444

Follow up of special histotypes including sarcomas

ESGO eAcademy, Nicholas Reed, 62443

Follow up after the treatment of endometrial cancer

ESGO eAcademy, ENRICO SARTORI, 62442

Endometrial cancer: Familial risk and its management

ESGO eAcademy, Usha Menon, 62441

Imaging strategies in the follow-up of endometrial cancer

ESGO eAcademy, Nandita de SOUZA, 62439

Imaging strategies for follow up

ESGO eAcademy, Manuela LUDOVISI, 62440

The Role of the Pathologist in Planning Follow up

ESGO eAcademy, Sigurd Lax, 62438

Take home message of State of the Art Conference

ESGO eAcademy, Tiziano Maggino, 62434

Take home message of State of the Art Conference

ESGO eAcademy, David Cibula, 62435